Merck May Face $2 Bil. Tax Bill; Medco Transactions Subject Of IRS Notice
Executive Summary
Merck is facing a potential $2 bil. back tax liability arising out of a "partnership transaction" tied to the 1993 Medco acquisition
You may also be interested in...
GSK Contests $5.2 Bil. Tax Bill After IRS Decision On Zantac Transfer Pricing
GlaxoSmithKline and the Internal Revenue Service are headed to court over the IRS' conclusion that the company owes $5.2 bil. for unpaid taxes, penalty charges and interest
MERCK MARKET SHARE ON MEDCO FORMULARIES REACHES 12%, UP FROM 10%; MERCK WILL NOT BROADEN PRODUCT LINE TO MAINTAIN MARKET SHARE, CEO GILMARTIN TELLS NYSSA
Merck products have climbed to a 12% share of Medco formulary product sales, Merck Chairman and CEO Ray Gilmartin told a meeting of the New York Society of Security Analysts Nov. 29.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011